Search

Displaying results 1961 - 1970 of 6949 in total
  1. Drug

    Bismuth subnitrate

    go.drugbank.com/drugs/DB13209
    ApprovedWithdrawn

    Bismuth subnitrate, also referred to as bismuth oxynitrate or bismuthyl nitrate, is a highly water-soluble crystalline compound that has been used as a treatment for duodenal ulcers and anti-diarrheic

    Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
  2. Drug

    Vamorolone

    go.drugbank.com/drugs/DB15114
    ApprovedInvestigational

    option in patients for whom corticosteroid adverse effects are intolerable or otherwise unacceptable. … [L48671,L48676] In December 2023, it was approved in the EU for the treatment of patients ≥4 years of age.[L49505]

    Categories: Corticosteroids for Systemic Use, Corticosteroids for Systemic Use, Plain
  3. Drug

    Pemoline

    go.drugbank.com/drugs/DB01230
    ApprovedIllicitWithdrawn

    In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons.

    Categories: Psychostimulants, Agents Used for ADHD and Nootropics
  4. Drug

    Trimethadione

    go.drugbank.com/drugs/DB00347
    ApprovedWithdrawn

    An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378)

  5. Drug

    Boceprevir

    go.drugbank.com/drugs/DB08873
    ApprovedWithdrawn

    with [DB00811], [DB00008], and [DB00022] as first line therapy for Hepatitis C [A19593]. … Boceprevir is available as a fixed dose product (tradename Victrelis) used for the treatment of chronic Hepatitis C.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  6. Drug

    Valbenazine

    go.drugbank.com/drugs/DB11915
    ApprovedInvestigational

    [A261125] On August 2023, valbenazine was again approved by the FDA for the treatment of chorea associated with Huntington's disease respectively. … [A261165] On April 2017, valbenazine was approved by the FDA under the brand name INGREZZA as the first and only approved treatment for adults with Tardive Dyskinesia (TD).

  7. Drug

    Imdevimab

    go.drugbank.com/drugs/DB15940
    ApprovedInvestigational

    Imdevimab is a monoclonal antibody combined with [casirivimab] in Regeneron's antibody cocktail known as REGEN-COV2 for the treatment of COVID-19. … They are reserved for Emergency Use Authorization (EUA) only.[L23524] In November 2021, the same indication was approved by the EMA.

    Categories: Antiinfectives for Systemic Use, Approved Treatments for COVID-19
  8. Drug

    Dutasteride

    go.drugbank.com/drugs/DB01126
    ApprovedInvestigational

    Dutasteride was approved by the FDA in 2001 for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men as monotherapy or in combination with the α-adrenergic antagonist [tamsulosin] to … However, unlike finasteride, dutasteride is not yet indicated for the treatment of androgenic alopecia although it was demonstrated to be effective in several randomized, double-blind, placebo-controlled

  9. Drug

    Cinchocaine

    go.drugbank.com/drugs/DB00527
    ApprovedVet approved

    A local anesthetic of the amide type now generally used for surface anesthesia.

    Categories: Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Anesthetics for Topical Use
  10. Drug

    Apomorphine

    go.drugbank.com/drugs/DB00714
    ApprovedInvestigational

    [A203618] Apomorphine has also been investigated as an emetic, a sedative, a treatment for alcoholism, and a treatment of other movement disorders.

    Categories: Serotonin Receptor Antagonists, Nonergot-derivative Dopamine Receptor Agonists